ABT

Abbott Laboratories

HealthcareMedical DevicesNASDAQ

$85.60

-$2.12 (-2.47%)today

Conviction

0/ 10

Fair Value$132.12

Upside+54.35%

Signal0

Market Cap$178.1B

52W Range$100.88–$139.06

Next EarningsApr 16

Price History

FAIR VALUE ANALYSISMonte Carlo · 5,000 runs · 99% valid

Fair Value$77.02

Current Price$103.99

Upside / Down-25.9%

P(Undervalued)7.3%

P(20%+ Up)0.7%

P(15%+ Down)75.2%

Fair Value Distribution — percentile bands

7.3% of simulations place fair value above current price

WHAT IS PRICED IN

Revenue-Based Reverse DCF

9.6%/yr

±5.4% · revenue growth to justify current price

FCF-Based Reverse DCF

8.2%/yr

±3.1% · FCF growth to justify current price

THE GAP

Market pricing margin expansion or capex normalization

Premium Content

Upgrade to premium for full distribution data, sensitivity analysis, and segment breakdowns.

Quick Take

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide.

Trailing P/E27.5x

Forward P/E16.8x

P/S4.0x

EPS (TTM)$3.72

Analyst Target$132.12

Analyst Upside54.3%

No Eagle analysis yet. Request a full review including conviction score, bull/bear cases, and thesis.

Bull Case

No analysis yet

Bear Case

No analysis yet

Research Feed

sec_10kFeb 28

Conviction: unchanged

ABT FY2025 10-K: CGM Dominance + Exact Sciences Overhang

Abbott delivered solid FY2025 results led by CGM dominance (.6B, +17%) and MedDevices segment growth (+12%), with expanding operating margins (16.3%→18.2%). The transformative pending acquisition of E...